Tenecteplase & Thrombectomy: Improved Stroke Outcomes
- Patients experiencing acute ischemic stroke due to large-vessel occlusion may benefit from intravenous tenecteplase administered before endovascular thrombectomy, according to research published in the New England journal...
- The open-label trial, conducted in China by Zhongming Qiu, M.D., and colleagues from the Second Affiliated Hospital of Army Medical University, involved patients eligible for thrombolysis within 4.5...
- The primary outcome measured was functional independence, assessed using the modified Rankin scale. The results showed that 52.9% of patients in the tenecteplase-thrombectomy group achieved functional independence at...
News Directory 3 reports on a groundbreaking study revealing that administering tenecteplase before thrombectomy significantly elevates stroke outcomes. The research, published in the New England journal of Medicine, highlights improved functional independence in acute ischemic stroke patients at the 90-day mark. specifically, the study, conducted in China, indicates that using tenecteplase before thrombectomy led to higher rates of functional independence compared to thrombectomy alone. Moreover, the study also suggests tenecteplase use may promote reperfusion prior to thrombectomy. While the authors acknowledge the need for further investigation, this approach offers a promising avenue for enhancing recovery. Discover what’s next as medical professionals refine stroke treatment protocols.
Tenecteplase Enhances Stroke Recovery When Used Before Thrombectomy
Updated May 26, 2025
Patients experiencing acute ischemic stroke due to large-vessel occlusion may benefit from intravenous tenecteplase administered before endovascular thrombectomy, according to research published in the New England journal of Medicine.The study, coinciding with the European Stroke Organisation Conference in Helsinki, found a link between this approach and higher functional independence at 90 days.
The open-label trial, conducted in China by Zhongming Qiu, M.D., and colleagues from the Second Affiliated Hospital of Army Medical University, involved patients eligible for thrombolysis within 4.5 hours of stroke onset. Participants were randomly assigned to receive either intravenous tenecteplase followed by endovascular thrombectomy or endovascular thrombectomy alone.
The primary outcome measured was functional independence, assessed using the modified Rankin scale. The results showed that 52.9% of patients in the tenecteplase-thrombectomy group achieved functional independence at 90 days, compared to 44.1% in the thrombectomy-alone group. This translates to an unadjusted risk ratio of 1.20.
Researchers also noted that 6.1% of patients in the tenecteplase-thrombectomy group experienced prosperous reperfusion before thrombectomy, compared to only 1.1% in the thrombectomy-alone group. After thrombectomy, successful reperfusion rates were 91.4% and 94.1%, respectively.
Symptomatic intracranial hemorrhage within 48 hours occurred in 8.5% of patients receiving tenecteplase-thrombectomy and 6.7% of those receiving thrombectomy alone. Mortality rates at 90 days were 22.3% and 19.9%, respectively.
The authors cautioned that the lack of consistent significant benefit across secondary outcomes tempers the strength of the primary finding.
The China Shijiazhuang Pharmaceutical Company recomgen Pharmaceutical provided partial funding for the study.
What’s next
Further research is needed to confirm these findings and to explore the optimal use of tenecteplase in stroke treatment protocols. Future studies coudl also investigate the long-term effects of this combined approach on patient outcomes.